Herpesvirus procapsids and concatameric viral DNA accumulate in the nuclei of infected cells. The procapsids consist of a roughly spherical proteinaceous shell surrounding an inner protein shell or scaffold (16, 24, 36) . To initiate DNA packaging, an enzyme called the terminase is believed to scan the viral DNA in search of genomic ends, cleave the concatemer into single genomes, engage the procapsid at a portal vertex designed for the passage of the DNA, and drive the genome into capsids through the hydrolysis of ATP.
Current evidence supports the hypotheses that the herpes simplex virus (HSV) terminase comprises the products of U L 15, U L 28, and U L 33 (pU L 15, pU L 28, and pU L 33, respectively), whereas the portal vertex consists of a dodecamer of the U L 6 protein (pU L 6). These hypotheses are supported by the observations that (i) pU L 6, pU L 15, pU L 28, and pU L 33 are each essential for DNA packaging (2, 5, 25, 26, 34, 44) ; (ii) epitopes of these proteins are present on the external surface of viral capsids, and at least pU L 15 and pU L 28 are associated with procapsids (23, 31, 41) ; (iii) pU L 15 interacts with the pU L 28 moiety of a pU L 28/pU L 33 complex in infected cells (9, 18, 19, 43) ; (iv) pU L 15 contains an ATPase-like motif that is essential for viral replication (13, 45) ; (v) pU L 28 binds DNA sequences known to be required for the formation of normal DNA termini (1, 17) ; and (iv) pU L 6 forms a dodecameric ring in vitro with a size and conformation that match the dimensions of capsid vertices and portal vertices of some bacteriophages (23, 37) .
The main focus of the current study concerns a key question that distinguishes two models of DNA packaging: specifically, whether the terminase engages the portal vertex in the cytoplasm or in the nucleus. If the terminase were to engage the portal in the cytoplasm, it follows that portal assembly into the procapsid would also incorporate the bound terminase. This would imply that the entire procapsid, with incorporated terminase, would then scan viral DNA in search of genomic ends. On the other hand, if the terminase were imported into the nucleus separately from the portal, it would be free to scan the DNA independently of the procapsid and, once bound to target DNA sequences, could engage the portal vertex for eventual DNA cleavage and translocation into the capsid. The latter mechanism is similar to that used by many bacteriophage terminases (4, 6, 11) .
Where the HSV terminase forms in the cell and where the portal and terminase interact have been addressed previously using transient expression assays. For example, transiently expressed pseudorabies virus pU L 28 localizes in the cytoplasm unless coexpressed with HSV type 1 (HSV-1) pU L 15, suggesting that pU L 15 is responsible for the import of the terminase complex (20) . On the other hand, pU L 6 was also shown to import pU L 28 into the nucleus when the proteins were coexpressed, and mutations that precluded the nuclear importation of pU L 6 caused coexpressed pU L 15 to remain in the cyto-plasm, despite the fact that pU L 15 localizes in infected cell nuclei by 12 h after infection (5, 40, 45) . The transient expression assays argue that a terminase/portal complex forms in the cytoplasm and is then incorporated into the nucleus, where it would then presumably form a nidus for procapsid formation. In studies using infected cells, however, pU L 6 was not found to coimmunoprecipitate with pU L 28, pU L 15, or pU L 33 (9, 43) . Because the lysis conditions were mild in these studies, it was suggested that the terminase formed in the cytoplasm but that the portal and terminase interacted elsewhere. These interpretations were complicated by (i) the possibility that antibodies can interfere with interactions between proteins and (ii) uncertainty as to whether the lysates in which the interactions occurred were truly derived from the cytoplasm.
The current study clarifies previously described immunoprecipitation results to indicate that the putative terminase complex of pU L 15, pU L 28, and pU L 33 can be efficiently coimmunoprecipitated from lysates derived from either the cytoplasm or the nuclei of infected cells. Although pU L 6 could be coimmunoprecipitated with pU L 15 and pU L 28, these interactions were not detected unless cells were extracted using 1 M NaCl. We also show that pU L 15 contains a simian virus 40 T-antigenlike nuclear localization signal (NLS) required for the normal nuclear import of pU L 15 and pU L 28 in infected cells. This NLS was entirely dispensable for the nuclear import of the U L 6-encoded portal protein, further suggesting that the two complexes, the portal and the terminase, are imported into the nucleus independently of one another.
MATERIALS AND METHODS

Cells and virus.
Hep2 cell lines, Vero cell lines, and CV1 cell lines were obtained from the American Type Culture Collection (ATCC) and were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% newborn calf serum, 100 U/ml penicillin, and 100 g/ml streptomycin. Flp-In-CV1 cell lines were purchased from Invitrogen and maintained in DMEM supplemented with 10% fetal bovine serum, 100 U of penicillin per ml, 100 g/ml streptomycin, and 100 g/ml zeocin. CV15 and CV15M cell lines described herein were cultured in DMEM supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 g/ml streptomycin, and 200 g/ml hygromycin. The U L 15 deletion mutant was derived from HSV F strain [HSV-1(F)] (3, 15) . The U L 6 null mutant was derived from HSV-1 strain 17 (25) . The U L 28 null mutant, U L 28 insertion mutant 74li, and U L 28 truncation mutant 741s were derived from strain HSV-1(Kos) (18, 34) . Recombinant viruses vJB12, vJB13, vJB15, vJB16, and vJB19 are described below and in Tables 1 and 2 .
Antibodies. Separate polyclonal rabbit antisera recognizing the first 35 amino acids of pU L 15 (anti-pU L 15N), the C terminus of pU L 15 (anti-pU L 15C), and the entire pU L 28, pU L 33, and pU L 6 proteins were described previously (5, 9, 28, 29, 33) . Anti-FLAG mouse monoclonal antibodies were purchased from Sigma. Anti-lamin A/C mouse monoclonal antibodies were obtained from Santa Cruz Biotechnology. Rabbit polyclonal antibody directed against superoxide dismutase 4 (a cytoplasmic marker protein of 23 kDa) was purchased from Abcam. Anti-ICP35 mouse monoclonal antibody (MCA406) was purchased from Serotec. Goat anti-rabbit immunoglobulin G (IgG) conjugated to Alexa 488 (green) and goat anti-mouse IgG conjugated to Alexa 568 (red) were obtained from Molecular Probes.
Plasmids. Plasmids pBAD-I-SceI, containing the gene encoding the yeast I-SceI endonuclease, and pEPkan-S, containing aphAI (encoding kanamycin [Kan] resistance) adjacent to an I-SceI restriction site, were gifts from N. Osterrieder, Cornell University. Plasmid pCAGGS-nlsCre, expressing Cre recombinase, was a gift from Michael Kotlikoff, Cornell University. pJB112, containing U L 28 downstream of the human cytomegalovirus (CMV) early promoter/enhancer in pCDNA3, was described previously (43) .
To construct pJB437, a PCR amplicon from HSV-1(F) DNA containing the entire U L 6 coding sequence was cloned into pCDNA3 at the BamHI and EcoRI sites such that the gene was under the transcriptional control of the CMV promoter/enhancer. U L 15 genes fused to DNA encoding the FLAG epitope and deletion mutants of the fused gene are indicated in Fig. 2 and were amplified by PCR using pRB4120 (containing a cDNA of the U L 15 gene) as a template, followed by cloning into pCDNA3 at the HindIII and EcoRV sites. The deletions were confirmed by DNA sequencing.
To transfer U L 15 cDNA into a defined site within CV1 cells, a shuttle plasmid (designated pJB414) was constructed by producing a PCR amplicon (using pRB4120 as a template) that contained a His 6 tag fused to the C terminus of U L 15 cDNA. This amplicon was then inserted into the polylinker of the pCDNA5/FRT vector (Invitrogen) at the HindIII and EcoRV sites.
To construct a cell line expressing U L 15 lacking an NLS [pU L 15-NLS(Ϫ)], another shuttle plasmid, pJB509, was constructed. Thus, pJB502 [containing U L 15-NLS(Ϫ), as indicated in Fig. 2 ] was digested with HindIII and EcoRV, and the U L 15-containing DNA fragment was gel purified and cloned into pCDNA5/ FRT at the HindIII and EcoRV sites. In all cases, the constructs were confirmed by DNA sequencing and immunoblotting with appropriate antibodies.
A plasmid encoding the U L 15 NLS fused to enhanced green fluorescent protein (EGFP) was constructed by annealing oligonucleotides 5Ј-AGC TTA TGG GCC CAC CTA AGA AAC GGG CCA AGG TGC GG-3Ј and 5Ј-GAT CCC GCA CCT TGG CCC GTT TCTT AGG TGG GCC CAT A-3Ј (encoding an NLS) and cloning them into the HindIII and BamHI sites in the pEGFP-N1 vector (Clontech) such that they were in frame with the N terminus of EGFP. The genotype of the construct was confirmed by DNA sequencing.
Constructions of recombinant viruses. Recombinant viruses were constructed by en passant mutagenesis, a two-step Red-mediated recombination system described previously by Tischer et al. (35) . The Red recombination system was induced by heating log-phase Escherichia coli strain EL250 cells harboring the entire HSV-1(F) genome in a bacterial artificial chromosome (BAC) (32) for 15 min at 42°C, followed by chilling and preparation for electroporation. A Kan resistance gene (aphAI) was amplified by PCR using plasmid pEPkan-S as a template and the primer combinations listed in Table 1 . The resulting PCR products were flanked by sequences homologous to the target gene. The PCR products were then treated with DpnI to digest the template DNA and gel purified on agarose gels prior to transformation into electrocompetent EL250 bacteria. After electroporation, the competent cells were resuspended in 1.0 ml of LB broth, incubated at 32°C with shaking for 2 h, and then plated onto LB plates containing 50 g/ml Kan and 30 g/ml chloramphenicol (Cmp). After 24 h incubation at 32°C, the Kan r Cmp r colonies were screened by restriction fragment length polymorphism of BAC DNA for insertion of the Kan resistance cassette into the proper genomic locus.
For the second Red recombination event to simultaneously remove the Kan r cassette and insert the desired mutation, pBAD-I-SceI, encoding ampicillin (Amp) resistance and the SceI restriction endonuclease, was electroporated into bacteria bearing the BAC with the proper Kan r insertion. Cmp r Amp r Kan r colonies were selected and grown to early log phase, and 1% arabinose was added to induce the expression of the SceI restriction endonuclease. After incubation for 1 h at 32°C with shaking, the Red recombination system was induced by incubation in a 42°C water bath with shaking for 30 min, followed by a further incubation for 1 h at 32°C. The pBAD-I-SceI-containing bacteria were then plated onto LB plates containing Cmp, Amp, and 1% arabinose and incubated overnight at 32°C. Individual colonies were replica plated to identify Cam r /Kan s colonies, and the BAC DNA in these colonies was again characterized by restriction fragment length polymorphism, PCR, and DNA sequencing. BAC DNA with the proper mutation was cotransfected with a Cre expression plasmid, pCAGGS-nelsCre, into CV15 cells (a U L 15 complementing cell line) or rabbit skin cells (a cell line lacking U L 15) using Superfect reagents (QIAGEN) according to the manufacturer's protocol. It was anticipated that the expression of Cre recombinase would cause a deletion of the BAC vector sequences inasmuch as they were flanked by appropriate recombination sites (32) . Each recombinant virus was further subjected to two rounds of plaque purification. The genotypes of the recombinant viruses as indicated in Tables 1 and 2 were confirmed by Southern blot and PCR to ensure that the BAC was removed and the target gene was mutated as designed.
Constructions of cell lines. U L 15-expressing cell lines were constructed by using the Flp-In-CV1 system (Invitrogen) according to the manufacturer's protocol and as described previously (21) . Briefly, either pJB414 or pJB509 was cotransfected with a plasmid (pOG44) containing Flp recombinase under the control of a constitutive CMV promoter/enhancer into an engineered cell line (Flp-CV1). After recombination, cells resistant to hygromycin were selected by growth in DMEM supplemented with 10% fetal bovine serum and 200 g/ml hygromycin B.
Transfections and immunofluorescence microscopy. Glass coverslips in sixwell plates were seeded with 2.5 ϫ 10 5 cells/well Hep2 cells and were incubated overnight in growth medium. A transfection mixture containing 4.0 g of plasmid and 10 l of Lipofectamine 2000 was prepared according to the manufacturer's instructions. Briefly, transfection reagent was diluted into 250 l of OptiMEM, incubated for 5 min at room temperature, and mixed gently with plasmids in an additional 250 l OptiMEM. The transfection mixture was incubated for 20 min at room temperature and added to a 2.0-ml overlay of normal growth medium without antibiotics. Incubation was continued at 37°C in a humidified 5% CO 2 incubator for a further 24 h before the cells were fixed and examined by fluorescence or prepared for indirect immunofluorescence.
Preliminary indirect immunofluorescence assays indicated that it was necessary to reduce background staining of the pU L 28 antisera described previously (9) . To preadosorb the U L 28-specific antisera against proteins other than pU L 28, one 850-cm 2 roller bottle containing approximately 2 ϫ 10 8 Hep2 cells was infected with a U L 28 deletion virus (gCB) at a multiplicity of infection (MOI) of 5.0 PFU/cell. At 18 h postinfection (hpi), cells were harvested and washed extensively with phosphate-buffered saline (PBS). An acetone powder of the infected cells was prepared according to the protocol described previously by Sambrook et al. (30) . The powder was added to anti-U L 28 serum and PBS, making the final antiserum concentration 1%. The mixture was then mixed on a rotator at 4°C overnight, debris was removed by centrifugation at 10,000 ϫ g for 10 min at 4°C, and the diluted supernatant was used for indirect immunofluorescence as detailed below. The anti-pU L 6 rabbit polyclonal antiserum was preadsorbed in a similar fashion except that cells used for the preadsorption were previously infected with a U L 6 null mutant (25) .
Either 24 h after transfection or 18 h after infection, cells on glass coverslips were washed with PBS, fixed with 3% (wt/vol) paraformaldehyde (in PBS) for 10 min at room temperature, and then permeabilized with 0.2% Triton X-100 in PBS for 5 min. The coverslips were blocked with 10% human serum in PBS for 2 h at room temperature. Cells were reacted with the following primary antibodies diluted in 10% human serum and PBS at room temperature for 60 min: anti-FLAG monoclonal antibody (M2; Sigma) diluted 1:100, preadsorbed anti- , and visualized using a Nikon Eclipse E600 fluorescence microscope, with a 60ϫ Plan Apo objective. Images were captured with a cooled SensiCam charge-coupled-device camera. Image files were exported in TIF format for processing with Adobe Photoshop 6.0. Each experiment was repeated at least three times. Cell fractionation. Approximately 5.0 ϫ 10 7 CV1 cells were mock infected or infected with the indicated viruses at an MOI of 5 PFU/cell. Eighteen hours after infection, cells were harvested and washed with cold PBS, resuspended in 3.0 ml of buffer A (10 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 , 5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 10 g of aprotinin/ml), incubated on ice for 1 h, and Dounce homogenized (25 to 30 strokes), and the fractions were observed microscopically to ensure adequate cell lysis. The nuclei were pelleted by centrifugation at 1,000 ϫ g for 5 min, and the supernatant was stored as the cytoplasmic fraction. The pellets were then washed with excess cold buffer A twice, and 3.0 ml ice-cold radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA) containing a cocktail of protease inhibitors (as described above) was added. The mixture was incubated on ice for 30 min to extract nuclear proteins. The nuclear fraction was clarified by centrifugation at 14,000 rpm for 15 min in a microcentrifuge. Separately, equal amounts of 2ϫ RIPA buffer were added to the cytoplasmic fraction to ensure that immunoprecipitations from nuclear and cytoplasmic fractions were performed under similar conditions. The cytoplasmic and nuclear extracts and nuclear pellets were denatured by boiling in sodium dodecyl sulfate (SDS) and mercaptoethanol and electrophoretically separated on separate lanes of 12% denaturing polyacrylamide gels, or the extracts were divided into three equal aliquots and subjected to immunoprecipitation with either anti-pU L 15N, anti-pU L 28, or anti-pU L 33 antibody.
Immunoprecipitation and immunoblotting. Immunoprecipitation and immunoblotting were performed as previously described (43) . In the case of pU L 6 immunoprecipitation and immunoblotting, the virus-infected cells were treated with RIPA buffer that was unsupplemented or supplemented with various concentrations of NaCl as indicated in Results. The antisera used for immunoprecipitation were diluted 1:100. The primary antibodies for immunoblotting were diluted in PBS plus 2% bovine serum albumin as follows: anti-pU L 6 was diluted 1:1,000, anti-pU L 15C was diluted 1:1,000, anti-pU L 28 was diluted 1:1,000, antipU L 33 was diluted 1:400, anti-FLAG (designated M2) was diluted 1:2,000, antilamin A/C mouse monoclonal antibodies were diluted 1:200, and anti-superoxide dismutase 4 rabbit polyclonal antibodies were diluted 1:1,000. Horseradish peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG diluted 1:5,000 in PBS plus 2% bovine serum albumin was reacted with the primary antibodies. Bound immunoglobulins were revealed by enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech).
Virus replication assay. Cells in 25-cm 2 flasks were infected with viruses (indicated in Table 2 ) at an MOI of 0.01 PFU/cell. After adsorption for 2 h at 37°C with shaking, the inoculum was removed, and the cells were washed with CBS buffer (40 mM citric acid, 10 mM KCl, 135 mM NaCl [pH 3.0]) to remove residual infectivity. The cells were washed sequentially with excess PBS and medium 199 supplemented with 1% bovine serum and overlaid with 5 ml DMEM supplemented with 5% newborn calf serum and antibiotics. Twenty-four hours after infection, virus was harvested by three cycles of freezing and thawing. Infectivity was determined by plaque assay on monolayers of cells as indicated in Table 2 . Each experiment was repeated three times.
RESULTS
pU L 15, pU L 28, and pU L 33 form a complex in the cytoplasm and nucleus. Previously, we reported that pU L 15, pU L 28, and pU L 33 of HSV-1(F) form a complex in transiently transfected cells and virus-infected cells (43) . To determine whether the complex forms initially in the cytoplasm or nucleus, CV1 cells were mock infected or infected with HSV-1(F), and cytoplasmic and nuclear lysates were prepared at 18 hpi. (Fig. 1) . Immunoblots of the lysates were then probed with antibodies directed against superoxide dismutase 4, an exclusively cytoplasmic protein, and anti-lamin A/C, an exclusively nuclear protein. Figure 1A shows that superoxide dismutase 4, with an apparent M r of 23,000, was readily detected in the cytoplasmic lysate of mock-infected cells and virus-infected cells but was not detectable in nuclear lysates. In contrast, immunoblotting with lamin A/C antibody (Fig. 1B) showed that lamin A/C was present exclusively in the nuclear fractions of mock-and HSV-1(F)-infected cells (Fig. 1 , lanes marked M/N and F/N, respectively). Similar results were obtained with lysates prepared at 12 h after infection (data not shown). These data indicate that the cytoplasmic and nuclear fractions were appropriate for subsequent analyses to determine the cytoplasmic or nuclear distribution of the U L 15-, U L 28-, and U L 33-encoded protein complex.
The nuclear and cytoplasmic fractions were subjected to immunoprecipitation with antibodies directed against either Figure 1C shows that pU L 15 was immunoprecipitated by antiserum directed against the N-terminal 35 amino acids of pU L 15 in roughly equal amounts from both the cytoplasmic and nuclear fractions (lanes 2 and 6). Moreover, pU L 15 was coimmunoprecipitated with pU L 28 or pU L 33 antibody from both the cytoplasmic and nuclear fractions (Fig. 1C , lanes 3 and 4 and lanes 7 and 8, respectively). In contrast, no pU L 15 was detected in mock-infected cells (Fig. 1C, lanes 1 and 5) . That all three proteins were coimmunoprecipitated was also determined by immunoblotting with all three antibodies (not shown). These results indicate that the complex of pU L 15, pU L 28, and pU L 33 is detectable in the cytoplasm and nuclei of infected cells.
Identification of a functional NLS in pU L 15. The simplest explanation for the results obtained thus far is that the pU L 15/ pU L 28/pU L 33 complex forms initially in the cytoplasm and is imported into the nucleus. Because we could not formally exclude the possibility that some nuclear protein leaked into the cytoplasmic extracts during preparation, additional experiments were performed to confirm the conclusion that the putative terminase complex forms in the cytoplasm. We reasoned that if one of the proteins was responsible for nuclear import of the complex and the complex formed in the cytoplasm, then ablation of the NLS in that protein should preclude the nuclear import of the entire complex. Therefore, the amino acid sequences of pU L 15, pU L 28, and pU L 33 were scanned in silico for putative NLSs using PSORT II (http: //psort.nibb.ac.jp). With the caveat that many NLSs are not detectable by such programs (12) , the results of this analysis indicated that only pU L 15 contained a canonical NLS at amino acids 183 to 189 (PKKRAKV [pattern 7]). This region was similar to the NLS of polyomavirus large T antigen and matched the consensus sequence K(K/R)X(K/R). A series of experiments was then undertaken to determine if this sequence could function as an NLS and, more importantly, if it was necessary for the nuclear import of pU L 15 and the putative terminase complex. As a first step in this regard, a series of pU L 15 deletion mutants fused to an N-or C-terminal FLAG epitope was constructed (diagrammed in Fig. 2 ) and verified by DNA sequencing and immunoblotting (data not shown). The various U L 15 expression plasmids were then transfected into Hep2 cells, and the intracellular distribution of pU L 15 was determined by indirect immunofluorescence microscopy using an anti-FLAG monoclonal antibody.
As shown in Fig. 3 , full-length pU L 
These data indicated that amino acids between positions 180 and 212 were necessary for the nuclear localization of pU L 15, consistent with the potential NLS (identified above) located at amino acids 183 to 189. The finding that this was a likely NLS was confirmed inasmuch as a deletion of only amino acids 182 to 189 caused pU L 15 to remain in the cytoplasm (Fig. 3,  bottom) .
To determine whether 183-PKKRAKV-189 was sufficient to serve as an NLS, DNA encoding this motif was fused in frame to the N terminus of the gene encoding EGFP. Plasmids encoding EGFP and the putative pU L 15 NLS fused to EGFP were transfected into Hep2 cells, and the intracellular distributions of EGFP and the chimeric protein were determined by fluorescence microscopy. As shown in Fig. 4 , in cells expressing EGFP alone, the fluorescence was diffuse and localized within both the cytoplasm and nucleus. In contrast, the NLS-EGFP localized predominantly within the nucleus. These observations indicate that pU L 15 contains a functional NLS between amino acids 183 and 189. pU L 28 targeting to the nucleus in infected cells requires the NLS of pU L 15. Thus far, previously reported studies were conducted using transiently expressed proteins in uninfected cells. Because it is possible that in infected cells, other viral proteins might affect the nuclear import of terminase components, we constructed recombinant viruses as detailed in Materials and Methods. Genotypes of viruses used in these studies are listed in Table 2 and are as follows: vJB12 lacks the pU L 15 NLS as a consequence of a deletion of U L 15 codons 182 to 189, vJB13 contains DNA encoding the FLAG epitopic tag fused to the C terminus of pU L 15, and vJB16 was derived from vJB13 and encodes both the U L 15-FLAG fusion and a deletion of the putative pU L 15 NLS.
That the recombinant viruses expressed FLAG-tagged pU L 15 was determined by infection of cells followed by immunoblotting with anti-FLAG antibody. As shown in Fig. 5 , the FLAG-tagged pU L 15 was readily detected in lysates of cells infected with either vJB13 or vJB16 (Fig. 5A, lanes 4 and 5) . In contrast, no FLAG-specific immunoreactivity was detected in lysates of cells that were mock infected (Fig. 5A, lane 1) or that were infected with wild-type HSV-1(F) (Fig. 5A, lane 3) or the U L 15 deletion mutant (Fig. 5A, lane 2) . The finding that the FLAG epitope was fused to pU L 15 was further confirmed upon probing the same blot with anti-pU L 15C antibody. Specifically, the bands containing FLAG-specific immunoreactivity also reacted with the pU L 15-specific antiserum. (Fig. 5B) .
To test the effects of the deletion of the pU L 15 NLS and insertion of the FLAG epitope at the pU L 15 C terminus on viral replication, Vero cells were infected with 0.01 PFU per cell wild-type HSV-1(F) or the recombinant virus vJB13 or vJB16. At 24 hpi, the yields of infectious virus were determined by plaque assay on Vero cells (in the case of vJB13) or a U L 15 complementing cell line (for vJB12 and vJB16). As shown in Table 2 , vJB13 replicated in Vero cells to titers that were similar to those of the wild-type virus, indicating that the insertion of the FLAG epitope into the C terminus of pU L 15 did not greatly affect virus replication. In contrast, viruses lacking the NLS, whether they encoded a FLAG-tagged or untagged pU L 15 (vJB12 and vJB16, respectively) ( Table 2 ), replicated to titers in Vero cells that were reduced more than 100,000-fold relative to those of wild-type HSV-1(F) or vJB13 bearing a FLAG-tagged pU L 15 with an intact NLS.
To ensure that the reduction in titer was a consequence of a deletion of the pU L 15 NLS, the NLS deletions in the recombinant BACs bJB12 and bJB16 were restored by using en passant mutagenesis, as described in Materials and Methods and as described previously (35) , to yield the BACs bJB15 and bJB19, respectively. Viruses derived from the transfection of these BACs into rabbit skin cells were designated vJB15 and vJB19, respectively. Infection of Vero cells with these viruses followed by titration of infectivity by plaque assay 24 h later indicated that they replicated as well as wild-type virus HSV-1(F) ( Table 2 ). Together, these data indicate that while an insertion of the FLAG epitope into pU L 15 did not affect virus yields, pU L 15 amino acids 182 to 189 were essential for virus replication.
To determine the role of the pU L 15 NLS in the nuclear import of pU L 28, Hep2 cells were mock infected or infected with vJB13, vJB16, or vJB19 at an MOI of 0.1 PFU/cell. At 18 hpi, cells were fixed and permeabilized and reacted with preadsorbed anti-pU L 28 rabbit polyclonal antiserum and anti-FLAG mouse monoclonal antibody, followed by reaction with the appropriate conjugated secondary antibodies and Hoechst stain to identify host chromosomal DNA. As shown in Fig. 5C , little immunofluorescence was detected in mock-infected cells, indicating that the antibodies did not recognize host proteins. In cells infected with vJB13, encoding a FLAG-tagged pU L 15, or vJB19, bearing a restored NLS within FLAG-tagged pU L 15, pU L 28-and pU L 15-specific immunofluorescence colocalized predominantly in cell nuclei. In contrast to these results, pU L 15-specific and pU L 28-specific immunofluorescence localized mostly in the cytoplasm of cells infected with vJB16 lacking the U L 15 NLS. This pattern of immunofluorescent staining was present in approximately 80% of over 300 cells examined (data not shown). These results indicate that the NLS of pU L 15 is required for the normal intranuclear localization of pU L 28.
We next wanted to determine whether the interaction between pU L 15 and pU L 28 was necessary for the nuclear import of the latter, as might be expected if the proteins interact in the cytoplasm, followed by nuclear import of the complex via recognition of the pU L 15 NLS. To test this possibility, we used two recombinant viruses bearing two different mutations in U L 28. In cells infected with the 741i recombinant virus, bearing an insertion of the amino acids ARSR at position 741 of U L 28, viral replication occurs, and pU L 15 and pU L 28 coimmunoprecipitate normally (18) . In cells infected with the 741s virus, bearing an insertion encoding ARS stop at position 741, viral replication does not occur, and pU L 28 coimmunoprecipitates with pU L 15 poorly (18) . The hypothesis that pU L 15 interacts with pU L 28 to transport it to the nucleus predicts that pU L 28 should be located in the cytoplasm of cells infected with 741S but in the nuclei of cells infected with 741i.
Hep2 cells were infected with gCB (a U L 28 null mutant virus), HSV-1(F), 741s, or 741i at an MOI of 0.1 PFU/cell, and the intracellular localization of pU L 28 was determined 18 hpi by immunofluorescence using preadsorbed antipU L 28 antiserum. As a marker of HSV-infected nuclei, cells were also stained with anti-ICP35 monoclonal antibody (MCA406; Serotec). As shown in Fig. 6 , no pU L 28-specific immunofluorescence was visualized upon immunostaining of gCB-infected cells, despite prominent ICP35-specific immunostaining indicating that the cells were infected (Fig.  6A, panels a through d) . This indicated that the preadsorbed (Fig. 6A , panels e through h). In cells infected with U L 28 mutant 741s, pU L 28 localized primarily in the cytoplasm (Fig. 6A , panels i through l), whereas pU L 28 localized in the nuclei of cells infected with 741i (panels m through p). To ensure that pU L 15 was expressed in infected nuclei, nuclear pellets of cells infected with HSV-1(F), 741s, and the U L 15 and U L 28 null mutants were subjected to immunoblotting with the pU L 15 antiserum. As shown in Fig. 6B , infected nuclei contained two proteins with apparent molecular weights of approximately 83,000 and 72,000 that reacted with the pU L 15 antiserum. That these were products of pU (Fig. 7A, lane 4) . Similar to the results with pU L 28, pU L 33 coimmunoprecipitated from the cytoplasmic fraction reacted with either antipU L 15 (Fig. 7B, lane 2) or anti-pU L 28 antibodies (Fig. 7B, lane  3) , and pU L 15 was coimmunoprecipitated from the cytoplasmic fraction by anti-pU L 28 (Fig. 7C, lane 3) and anti-pU L 33 (Fig. 7C, lane 4) antisera.
These observations ruled out the possibility that the deletion of codons 183 to 189 of U L 15 precluded an interaction with pU L 28 and pU L 33 and were consistent with above-described data (Fig. 1, 5 , and 6) indicating that the complex of pU L 28, pU L 15, and pU L 33 forms in the cytoplasm of virus-infected cells.
To determine the effects of the pU L 15 NLS on nuclear forms of the putative terminase, a similar experiment was performed using nuclear extracts. The results shown in Fig. 7 and repeated in at least three separate experiments indicated that pU L 15, pU L 28, and pU L 33 were immunoprecipitated from the nuclear fractions of cells infected with vJB12 with their cognate antibodies (Fig. 7A, lane 7, C, lane 6, and B, lane 8, respectively) . This was not surprising, given the observation that immunofluorescence specific for pU L 15 and pU L 28 was detected within the nuclei of vJB16-infected cells by indirect immunofluorescence (Fig. 5) , and pU L 33 is normally present in the cytoplasm and nucleus late in infection (28) .
In stark contrast to the results with cytoplasmic extracts of cells infected with vJB16, however, coimmunoprecipitation of pU L 15, pU L 28, and pU L 33 from nuclear extracts was, at best, inefficient. Specifically, pU L 15 did not coimmunoprecipitate with detectable pU L 28 or pU L 33 (Fig. 7, lane 6) , and pU L 33 did not coimmunoprecipitate with detectable pU L 15 or pU L 28 (Fig. 7, lane 8) . Moreover, the anti-pU L 28 antiserum coimmunoprecipitated no detectable pU L 15 and only a small amount of pU L 33 (Fig. 7, lane 7) . These observations were also in contrast to the results obtained upon immunoprecipitation of pU L 15, pU L 28, and pU L 33 from nuclear extracts of cells infected with wild-type HSV-1(F) (Fig. 1) . These data suggest that efficient formation of the pU L 15/pU L 28/pU L 33 complex requires that interactions between these proteins occur in the cytoplasm of cells infected with wild-type viruses. We speculate that in the absence of a cytoplasmic interaction, interactions in the nucleus either cannot occur or occur only very inefficiently. Alternatively, the data do not exclude the possibility that the interactions between pU L 15, pU L 33, and pU L 28 within the nucleus require amino acids 182 to 189, whereas interactions in the cytoplasm do not.
The portal encoded by pU L 6 is translocated into the nucleus independently of pU L 15. We reasoned that if pU L 6 and pU L 15 were to interact in the cytoplasm, retention of some pU L 15 in the cytoplasm by the deletion of its NLS should also retain pU L 6 in the cytoplasm in both infected and uninfected cells.
To test these possibilities, pU L 15-FLAG with or without its NLS was transiently coexpressed with pU L 6 in Hep2 cells, and the subcellular localizations of pU L 6 and pU L 15 were determined by immunofluorescence using an anti-pU L 6 polyclonal antiserum and anti-FLAG monoclonal antibody to detect pU L 15. Nuclei were identified with Hoechst stain. As expected, when full-length pU L 15-FLAG and pU L 6 were coexpressed, both localized exclusively in cell nuclei (Fig. 8a to d ). In contrast, when pU L 15-FLAG-NLS(Ϫ) was coexpressed with pU L 6, the pU L 15-specific signal localized predominantly in the cytoplasm, whereas pU L 6-specific immunoreactivity localized in the nucleus in a smooth, even pattern (Fig. 8e to h ). This observation agrees with previous results indicating that both pU L 6 and pU L 15 can translocate to nuclei in the absence of other viral proteins but also indicates that these proteins can localize into nuclei independently of one another.
To investigate the effects of the pU L 15 NLS on the localization of pU L 6 in infected cells, Hep2 cells were infected with vJB13, vJB16, or vJB19 at an MOI of 0.1 PFU/cell, and the intracellular distributions of pU L 6 and pU L 15 were examined 18 hpi by indirect immunofluorescence as described above. As shown in Fig. 8m to p, pU L 15 localized predominantly in the cytoplasm of cells infected with vJB16 lacking the U L 15 NLS, whereas pU L 6 localized in small foci or larger globular regions within the nucleus. Parenthetically, this pattern of immunostaining was different from the smooth pattern obtained upon the transient expression of pU L 6 in uninfected cells (Fig. 8 , compare b and f with j, n, and s). In contrast, FLAG-tagged pU L 15 containing an NLS as in vJB13-infected cells or a restored NLS as in vJB19-infected cells localized in a diffuse pattern throughout the DNA replication compartment (27) , whereas pU L 6 localized in small foci or larger globular regions within or adjacent to the DNA replication compartment (Fig.  8i to l and r to u, respectively) . These data suggest that pU L 15 and pU L 6 are imported separately into the nucleus of the infected cell. pU L 15 lacking the NLS is a dominant-negative inhibitor of HSV-1 replication. As shown in Table 2 and as discussed above, deletion of the NLS of pU L 15 as in recombinant viruses vJB12 and vJB16 precluded viral replication in Vero cells. Of additional interest, however, was the observation that the pU L 15 NLS deletion mutant vJB12 also replicated to titers about 17-fold lower than that of the U L 15 null mutant in the U L 15 complementing cell line clone 17 (data not shown) and CV15 (Table 2) . Moreover, in U L 15 complementing cells, vJB12 replicated to titers about 33-fold lower than those of the corresponding genetically repaired virus vJB15 or wild-type HSV-1(F) ( Table 2 ). Inasmuch as the NLS-repaired virus vJB15 derived from vJB12 replicated in Vero cells normally, the limited replication of vJB12 in complementing cells was not attributable to a mutation other than a deletion of the NLS in U L 15. These data suggest that pU L 15 lacking an NLS interferes with the function of wild-type pU L 15 in the complementing cell lines.
To clarify whether the deletion of the NLS in pU L 15 created a dominant-negative protein, we constructed a new cell line, CV15M, containing pU L 15-NLS(Ϫ) as detailed in Materials and Methods. CV15M cells were infected with HSV-1(F), and the amount of infectious virus was determined by plaque assay. As shown in Table 2 for complementing the replication of viral mutants bearing lethal mutations in U L 15. These results also indicate that mutant pU L 15 lacking an NLS acts in a dominant-negative fashion to inhibit the replication of wild-type HSV.
Interaction between terminase components and the portal protein pU L 6. Previous attempts to coimmunoprecipitate putative terminase components and the portal protein were unsuccessful (9, 43) . Those results might be explained by the insolubility of the interacting proteins, the interference of pU L 6 interactions by antibody binding, or the possibility that the proteins do not interact in infected cells. A systematic study was therefore undertaken to determine conditions under which the pU L 6 protein could be solubilized and, if it could be solubilized, whether pU L 6 could be coimmunoprecipitated with terminase components.
Cells were infected with 5 PFU per cell of wild-type virus HSV-1(F) and were extracted in RIPA buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, and 1 mM EDTA. Alternatively, the cells were extracted in RIPA buffer supplemented with 500 mM NaCl, 1.0 M NaCl, 1.5 M NaCl, or 2 M NaCl (Fig. 9A) . In all cases, insoluble material was separated from soluble material by centrifugation, and proteins in the pellets and supernatants were treated with SDS sample buffer, followed by denaturing gel electrophoresis and immunoblotting with a pU L 6-specific antibody. As shown in Fig. 9A , some pU L 6 was soluble in the presence of RIPA buffer alone, although a substantial amount of the protein was not solubilized in RIPA buffer. Increasing the salt concentration did not greatly increase the amount of pU L 6 that was solubilized, at least as assessed by immunoblotting. Even infected cells extracted in 2 M NaCl retained some pU L 6 in the insoluble fraction (Fig. 9A, compare lanes 4, 8,  and 12 ).
pU L 6 solubilized in RIPA buffer and at various concentrations of NaCl was then subjected to immunoprecipitation with a pU L 6-specific polyclonal antibody, and the presence of pU L 6, pU L 15, pU L 28, and pU L 33 in the immunoprecipitates was assessed by immunoblotting. The results using RIPA buffer alone or containing 1 M NaCl are shown in Fig. 9B to D. As a control, cells infected with 5 PFU per cell of a U L 6 null virus were treated similarly. pU L 6 was readily immunoprecipitated from cells infected with HSV-1(F) that were lysed in the presence of unsupplemented RIPA buffer (Fig. 9B, lane 2) , but the immunoprecipitated material did not contain pU L 15, pU L 28 ( Fig. 9C and D,  lanes 2 ), or pU L 33 (data not shown). The finding that the immunoprecipitated protein was the product of U L 6 was confirmed by its absence from immunoprecipitation reactions in which lysates of cells infected with the U L 6 null virus were reacted with the pU L 6-specific antibody (Fig. 9B, lane 1) . The lack of coimmunoprecipitation of pU L 15, pU L 28, and pU L 33 with pU L 6 in RIPA lysates of HSV-1(F)-infected cells is consistent with previous observations suggesting that highly soluble pU L 6 does not interact with the terminase components pU L 15, pU L 28, and pU L 33. This result was also consistent with conclusions presented above indicating that pU L 6 does not interact with pU L 15 in the cytoplasm.
Like pU L 6 solubilized in RIPA buffer, pU L 6 extracted from infected cells in RIPA buffer containing 1.0 M NaCl was readily immunoprecipitated with the pU L 6-specific antibody (Fig. 9B, lane 3) , indicating that the high salt concentration did not affect the immunoreactivity of pU L 6 with its cognate antibody. In the negative control reaction, neither pU L 15 nor pU L 28 was coimmunoprecipitated with pU L 6 in 1 M NaCl extracts of cells infected with the pU L 6 deletion mutant ( Fig.  9C and D, lanes 1) . Importantly, pU L 15 was readily coimmunoprecipitated with pU L 6-specific antibody in extracts produced in the presence of 1.0 M NaCl (Fig. 9C, lane 3) . Whereas pU L 28 immunoreactivity was also detectable in the pU L 6 immunoprecipitates under these conditions, the pU L 28-specific signal was considerably weaker than that of pU L 15 (Fig. 9D, lane 3) . pU L 33 did not coimmunoprecipitate with pU L 6 in 1.0 M NaCl above background levels (data not shown). These results suggest that at least the pU L 15 and pU L 28 components interact with the portal encoded by U L 6 in infected cells, thus supporting previous results using heterologously expressed proteins (40) . The data also suggest that the pU L 6/pU L 15/pU L 28 complex is considerably less soluble than the pU L 15/pU L 28/pU L 33 complex in infected cells. Less solubility might be expected of proteins associated with the nucleus, cytoskeletal components, or large complexes (e.g., procapsids or portal rings) that must be disrupted. We did not perform indirect immunofluorescence to determine the localization of pU L 33 in these studies for the following reasons. First, pU L 33 is arguably smaller than the diffusion limit of the nuclear pore, and a portion would be expected to be imported into the nucleus independently of the pU L 15/ pU L 28/pU L 33 complex. Thus, any effects of the U L 15 NLS mutation on pU L 33 localization would be difficult to discern. This expectation is consistent with the observation that pU L 33 is present in both the cytoplasm and nucleus by immunofluorescence assay, even late in infection (28) . Second, pU L 33 interacts directly with pU L 28 but only indirectly with pU L 15 (43) . Thus, any influence of pU L 15 mutations on pU L 33 localization would likely be mediated through effects on pU L 28. These studies therefore focused primarily on the effects of U L 15 mutations on the localization of pU L 28.
Although the nuclear import of pU L 15 and pU L 28 is greatly affected by the ablation of the pU L 15 NLS, some pU L 15 and pU L 28 can be imported into the nucleus in the absence of the pU L 15 NLS. This is supported by both indirect immunofluorescence and immunoblots of nuclear lysates probed with pU L 15-and pU L 28-specific antibodies ( Fig. 5 and 7 ). (As a caveat, it should be noted that the signals on the immunoblots may not reflect the relative quantities of the probed proteins inasmuch as such quantification requires that the proteins be in the linear range of detection.) It is currently unclear how some pU L 15 lacking an NLS and pU L 28 are imported into the nuclei of cells infected with the mutant virus, although it seems likely that NLSs other than amino acids 183 to 189 of pU L 15 are used. In any event, the data indicate that the nuclear import of the pU L 15/pU L 28 complex is negatively affected in the absence of the classical NLS within pU L 15.
In nuclear lysates of cells infected with wild-type virus, pU L 15, pU L 28, and pU L 33 could be coimmunoprecipitated, suggesting that the interactions between these proteins are maintained in the nucleus after nuclear import. In contrast, these proteins either did not coimmunoprecipitate (pU L 15 and pU L 28) or coimmunoprecipitated poorly (pU L 28 and pU L 33) from nuclear lysates of cells infected with the viral mutant lacking the NLS within pU L 15. These data argue that in the event that the putative terminase does not form in the cytoplasm, components that become incorporated into the nucleoplasm through independent means cannot interact efficiently. We cannot exclude the possibilities that (i) the NLS of U L 15 is necessary for the interaction of these proteins in the nucleus but dispensable for interactions in the cytoplasm or (ii) the smaller amounts of proteins imported into nuclei in the absence of the pU L 15 NLS preclude the detection of coimmunoprecipitated proteins.
Interaction between the portal protein and terminase components. The current data suggest that pU L 6 is imported into the nucleus independently of the putative terminase components pU L 15, pU L 33, and pU L 28. This hypothesis is supported by the observations that (i) U L 6 is incorporated into the nucleus whether or not the NLS within pU L 15 is ablated and (ii) the pU L 6 purified from lysates produced under mild conditions did not contain either pU L 15 (Fig. 9C, lane 2) , pU L 28 (Fig. 9D,  lane 2) , or pU L 33 (data not shown). These conclusions are in contrast to those from previous studies in which pU L 6 was mutated such that it remained cytoplasmic and, when transiently expressed, precluded coexpressed pU L 15 from translocation into the nucleus (40) . These disparate results may be a consequence of transient expression in the previous study versus the use of infected cells in the current study. Given that in infected cells, the proteins of interest are expressed at physiological levels and in the presence of other viral proteins that likely influence the nuclear import of portal, capsid, and terminase components, we give more credence to the current results.
Although they use different routes to the intranuclear DNA packaging reaction, the current data also suggest that pU L 6 and the putative terminase interact (Fig. 9) . The possibility that such interactions can occur is also supported by (i) the coimmunoprecipitation of pU L 6 with pU L 28 and pU L 15 with pU L 6 when overexpressed in a recombinant baculovirus system (40), (ii) the observation that treatment with an antiviral drug directed against U L 6 decreases the incorporation of both pU L 6 and pU L 15 into capsids (22, 38) , and (iii) the finding that decreased amounts of pU L 15 associate with U L 6(Ϫ) capsids (46) . On the other hand, one to two copies of pU L 15 and pU L 28 and an unknown number of copies of pU L 33 can associate with capsids isolated from cells infected with a U L 6 deletion mutant, suggesting that the interactions of terminase proteins and the capsid also involve capsid components other than pU L 6 (7, 8) . It is also worth noting that like pU L 6, the U L 15, U L 28, and U L 33 proteins have been shown to associate with the external surface of the capsid, as might be expected when the terminase docks with the capsid (23, 41) .
It is of interest that pU L 15 coimmunoprecipitates with pU L 6 more readily than does pU L 28 or pU L 33. U L 15 and U L 28 coimmunoprecipitate with one another in 1 M NaCl (not shown); therefore, the relatively high amount of salt in the extraction buffer cannot fully explain why less pU L 28 than pU L 15 coimmunoprecipitates with pU L 6. Although this observation might simply reflect pU L 6-specific antibody interference with the pU L 28 interaction, it is also consistent with an emerging model in which pU L 15, as the ATPase subunit, is more intimately associated with the portal than its interaction partners encoded by pU L 28 and pU L 33. The latter two proteins interact directly with one another and might represent the DNA binding portion of the terminase (1, 43) . Supporting this model are the observations that pU L 15 is highly enriched in capsids believed to result from aborted DNA packaging events (type A capsids), whereas pU L 28 was not detected in these capsids (8) . In that work, it was speculated that in binding to the DNA, pU L 28 was lost from the capsid along with the DNA.
The relative insolubility of the pU L 6/pU L 15 complex suggests localization in the nucleus (14) , association with cytoskeletal elements, or interaction with larger complexes that must be disrupted by extraction in high salt. Such larger complexes might include the procapsid/terminase complex, which may or may not be associated with nuclear matrix loci that augment procapsid formation or function (10, 39, 42) . The resistance of the pU L 15/pU L 6 complex to extraction under mild conditions helps to explain previous and current results that show interactions between putative terminase components but not between the terminase and the portal protein (7, 43) . pU L 33 interacts directly with pU L 28 but only indirectly with pU L 15 (43) . We speculate that the inability to coimmunoprecipitate pU L 33 with pU L 6 reflects antibody interference or the rather stringent extraction conditions required to solubilize the portal/terminase complex. It seems unlikely that the result can be explained by the absence of pU L 33 from capsids inasmuch as a relatively stable association of pU L 33 with the capsid surface has been documented (7) .
Assuming that a single terminase complex mediates all terminase functions, the simplest model to explain the current results would propose that pU L 15, pU L 28, and pU L 33 form a complex in the cytoplasm. The complex is then imported into the nucleus via an NLS in pU L 15. The terminase then presumably identifies terminal ends of concatameric genomes. The terminase/DNA complex then interacts with the U L 6-encoded portal vertex primarily through the pU L 15 moiety, followed by the cleavage/packaging of the DNA. Further experimentation is clearly warranted to test aspects and implications of this model and to elucidate the reactions in more molecular detail.
